[1] Fontana RJ, Bjornsson ES, Reddy R, et al. The evolving profile of idiosyncratic drug-induced liver injury. Clin Gastroenterol Hepatol, 2023, 21(8):2088-2099. [2] Larrey D, Delire B, Meunier L, et al. Drug-induced liver injury related to gene therapy: A new challenge to be managed. Liver Int, 2024, 44(12):3121-3137. [3] Hosack T, Damry D, Biswas S. Drug-induced liver injury: a comprehensive review.Therap Adv Gastroenterol, 2023,16:17562848231163410. [4] 杨开宁,王梦梦,陈秀秀,等.不同护肝药物护佑抗痨治疗防治药物性肝损伤发生研究.实用肝脏病杂志,2023,26(3):384-387. [5] 卫栋萍,韩黎黎,凌佳慧,等.甘草酸二胺与复方甘草酸苷治疗环磷酰胺所致的药物性肝损伤患者疗效研究.实用肝脏病杂志,2023,26(3):388-391. [6] 中国医药生物技术协会药物性肝损伤防治技术专业委员会,中华医学会肝病学分会药物性肝病学组.中国药物性肝损伤诊治指南(2023年版).中华肝脏病杂志,2023,31(4):355-384. [7] Fontana RJ, Liou I, Reuben A, et al. AASLD practice guidance on drug, herbal, and dietary supplement-induced liver injury. Hepatology, 2023, 77(3):1036-1065. [8] Lewis JH, Korkmaz SY, Rizk CA, et al. Diagnosis, prevention and risk-management of drug-induced liver injury due to medications used to treat mycobacterium tuberculosis. Expert Opin Drug Saf, 2024, 23(9):1093-1107. [9] 李玥,马烁,刘越,等.TLR2和TLR4基因多态性及启动子区CpG岛甲基化与抗结核药物性肝损伤的关系.中华疾病控制杂志,2025,29(2):217-223. [10] Zhang J, Zang X, Lv J, et al. Changes in lipidomics, metabolomics, and the gut microbiota in CDAA-induced NAFLD mice after polyene phosphatidylcholine treatment. Int J Mol Sci, 2023, 24(2):1502-1512. [11] Wu L, Zhu Y, Zhu S, et al. Untargeted lipidomics analysis to discover lipid profiles and biomarkers of rabbit acne model and reveal action mechanism of isotretinoin. Drug Des Devel Ther, 2024, 18(1):4003-4016. [12] 高倩,陈璇,周轶群,等.五脂胶囊联合复方甘草酸苷治疗非酒精性脂肪性肝炎患者疗效临床研究.实用肝脏病杂志,2025,28(4):529-532. [13] 付小桐,曹春雨,李春,等.基于胆固醇代谢的复方甘草酸苷片配伍雷公藤多苷片减轻肝损伤机制.中国实验方剂学杂志,2025,31(2):46-55. [14] Kumar R, Kumar A, Kumar S. Acute liver failure from anti-tuberculosis drug-induced liver injury: An update. World J Hepatol, 2025, 17(5):e106618. [15] Cheng J, Zhu J, Chen R, et al. Genetic polymorphisms and anti-tuberculosis drug-induced liver injury: an umbrella review of the evidence. Int J Clin Pharm, 2025, 47(3):624-639. [16] 白建梅,刘英喆,田瑞雪,等.Chlorfortunone A通过调节TGF-β/Smad2通路抑制糖尿病肾病小鼠肾纤维化.中华内分泌代谢杂志,2025,41(2):145-151. [17] Ma HH, Zheng JY, Qiu YH, et al. Dengzhan Shengmai capsule ameliorates cognitive impairment via inhibiting ER stress in APP/PS1 mice. J Ethnopharmacol, 2025, 338(Pt 1):e119016. [18] Bessone F, Hernandez N, Medina-Caliz I, et al. Drug-induced liver injury in latin America: 10-year experience of the Latin American DILI (LATINDILI) network. Clin Gastroenterol Hepatol, 2025, 23(1):89-102. [19] Allison R, Guraka A, Shawa IT, et al.Drug induced liver injury - a 2023 update.J Toxicol Environ Health B Crit Rev, 2023,26(8):442-467. [20] 雷紫璇,桑蝶,兰波,等.曲妥珠单抗生物类似药HLX02与原研药联合帕妥珠单抗及化疗在HER-2阳性乳腺癌患者新辅助治疗中的疗效安全性及成本效益比较.中华肿瘤杂志,2025,47(6):517-524. |